EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease

Mehmet Kanbay iD, Sidar Copur, Mustafa Guldan, Lasin Ozbek, Francesca Mallamaci, Carmine Zoccali iD

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.14330 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Mehmet Kanbay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Glucagon-Like Peptide 1, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Obesity is a growing epidemic affecting approximately 40% of the adult population in developed countries with major health consequences and comorbidities, including diabetes mellitus and insulin resistance, metabolically associated fatty liver disease, atherosclerotic cardiovascular and cerebrovascular diseases and chronic kidney disease. Pharmacotherapies targeting significant weight reduction may have beneficial effects on such comorbidities, though such therapeutic options are highly limited. In this narrative review, we aim to evaluate current knowledge regarding dual agonist therapies and potential implications for managing fatty kidney and chronic kidney disease. Results and Conclusion Glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors are two novel classes of glucose‐lowering medications with potential implications and beneficiary effects on renal outcomes, including estimated glomerular filtration rate, albuminuria and chronic kidney disease progression. Recently, dual agonist therapies targeting glucagon‐like peptide‐1 and glucagon receptors, namely survodutide and cotadutide, have been evaluated in managing metabolically associated fatty liver disease, a well‐established example of visceral obesity. Fatty kidney is another novel concept implicated in the pathophysiology of chronic kidney disease among patients with visceral obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicGlucagon-Like Peptide 1Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsHumansGlucagonDiabetes Mellitus, Type 2ObesityGlomerular Filtration RateNon-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

diabetes mellitusfatty kidneyglucagonglucagon‐like peptide‐1metabolically associated fatty liver disease

Substanzen

Glucagon-Like Peptide 1Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagonGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
  • Nephrology, Dialysis and Transplantation Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
  • CNR-IFC, Research Unit of Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Institute of Clinical Physiology, Reggio Calabria, Italy.
  • Renal Research Institute, New York, New York, USA.
  • Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy.

ORCID-Profile: Mehmet Kanbay, Carmine Zoccali

Zitieren

APA

Kanbay, M., Copur, S., Guldan, M., Ozbek, L., Mallamaci, F., & Zoccali, C. (2025). Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14330

Vancouver

Kanbay M, Copur S, Guldan M, Ozbek L, Mallamaci F, Zoccali C. Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14330

BibTeX
@article{Kanbay2025,
  author = {Kanbay, Mehmet and Copur, Sidar and Guldan, Mustafa and Ozbek, Lasin and Mallamaci, Francesca and Zoccali, Carmine},
  title = {Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.14330}
}
Kostenlos starten →